Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

The FDA’s user free programs account for just under half of the agency’s budget—money that could be imperiled by the recent ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.